Inhibrx Biosciences, Inc. INBX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s cumulative cost basis?
- Inhibrx Biosciences, Inc. (INBX) reported cumulative cost basis of $14.85M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s cumulative cost basis changed year-over-year?
- Inhibrx Biosciences, Inc.'s cumulative cost basis decreased by 1.7% year-over-year, from $15.11M to $14.85M.